Banner Image Banner Image

Investors
& Media

Press Releases

Press Releases

All Releases
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
TG received guidance from the FDA allowing submission of a single NDA for Marginal Zone Lymphoma (MZL) and Follicular Lymphoma indications Completion of rolling submission for the MZL/FL NDA expected in 1H20 NEW YORK , Jan. 16, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics , Inc. (NASDAQ: TGTX), a
Jan 16, 2020
TG Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Presentation scheduled for Thursday, January 16, 2020 at 8:00 AM PT NEW YORK , Jan. 10, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss , the Company’s Executive Chairman and Chief Executive Officer, will present at the 38 th Annual J.P.
Jan 10, 2020